Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-09-23
Vale announces partial resumption of operations at the Fábrica Mine in Ouro Preto following court authorization and a Commitment Agreement with state authorities. This is a material operational event affecting production capacity and regulatory compliance, but does not fit a discrete named category (not a workforce reduction, M&A activity, or specific financial event). The company notes the resumption does not change production guidance, suggesting a phased operational recovery rather than a discrete transaction or restructuring.
View raw filing on EDGAR →
6-K
M&A activity
confidence 99%
filed 2026-09-23
EX-99.1
Afya Limited has entered into a binding merger agreement with Yduqs Participações S.A., combining two major Brazilian higher education platforms. The transaction involves Afya merging into Yduqs with Yduqs as the surviving entity, resulting in Afya shareholders holding 69.0% and Yduqs shareholders 31.0% of the combined company on a fully diluted basis. This is a material acquisition/change of control requiring shareholder approval and antitrust clearance, with an exchange ratio of 6.408347 new Yduqs shares per Afya share and expected closing by March 31, 2028.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-23
EX-99.1
Mesoblast announced FDA approval to implement a new potency assay (TIBA) for release and stability monitoring of its commercial Ryoncil product. This is a material regulatory advancement affecting the company's manufacturing and quality control processes for its lead FDA-approved product, but it does not fit the specific event categories of earnings release, M&A, executive changes, debt issuance, or other named types. The approval enhances product consistency and clinical effectiveness, making it operationally significant to a reasonable investor assessing the company's ability to commercialize and maintain Ryoncil.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-23
EX-99.1
Sequans received a notice from NYSE on September 14, 2026 that it is no longer in compliance with Section 802.01B of the NYSE Listed Company Manual due to average global market capitalization below $50 million combined with stockholders' equity less than $50 million. While the notice does not result in immediate delisting, the company has 90 days to submit a compliance plan and 9 months to cure the deficiency, or face delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-09-23
Item 8.01
Visa deposited $405 million into a litigation escrow account under its retrospective responsibility plan, triggering downward adjustments to conversion rates for class B-1, B-2, and B-3 common stock held by U.S. financial institutions. These conversion rate reductions resulted in dilution equivalent to a share repurchase, reducing as-converted share counts by approximately 1.1 million shares across the three classes. While this is a structured capital event tied to litigation funding rather than a traditional equity issuance, the mechanism—conversion rate adjustments that dilute existing shareholders—aligns with the dilutive effects disclosed under Item 3.02 frameworks and materially affects share counts and EPS.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 7.01
Moleculin announced the grant of Mexican Patent No. 436849 protecting its proprietary lung-targeted liposomal Annamycin technology through 2040, strengthening the company's global patent estate and providing long-term commercial protection for its lead clinical-stage asset.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-23
Item 8.01
Moleculin completed two dilutive equity issuances: (1) an ATM offering of 888,400 shares for $0.48 million in September 2026, and (2) a public offering of Series I Warrants to purchase 37,130,001 shares on August 3, 2026, with anti-dilution provisions that reduced the warrant exercise price from $0.75 to $0.51 per share following the ATM issuance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 8.01
BioCardia disclosed timing and progress updates on two regulatory milestones: (1) a planned Shonin pre-market submission to Japan's PMDA in Q4 2026 for CardiAMP HF with potential market clearance by Q4 2027, and (2) an intended De Novo pre-submission for the Helix Transendocardial Delivery Catheter System to the FDA this quarter. These are material operational and regulatory developments affecting the company's product pipeline advancement, though they do not constitute a completed transaction, earnings release, or other specifically-named event type. The disclosure is material because regulatory progress on clinical-stage therapeutics directly affects investor assessment of the company's near-term value drivers and commercialization prospects.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-09-23
Item 1.01
Patriot National Bancorp issued $10.0 million in aggregate principal amount of 8.5% Fixed to Floating Rate Subordinated Notes due 2036 to qualified institutional buyers pursuant to Subordinated Note Purchase Agreements. The unsecured subordinated notes are intended to qualify as Tier 2 capital, representing a material capital-raising event for the bank.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-23
Item 5.07
This is a clear disclosure of shareholder vote results from FutureFuel Corp.'s annual stockholders' meeting held on September 22, 2026. The filing reports voting outcomes on three matters: election of directors Paul A. Novelly, II and Richard P. Rowe; advisory approval of named executive officer compensation; and ratification of Grant Thornton LLP as independent auditor. All matters were approved. This is a textbook shareholder_vote_results event under Item 5.07, and the outcomes are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-23
Item 5.02
The Compensation Committee approved special grants of time-based and performance-based restricted share units to named executive officers (Robert A. Frist, Jr., Michael M. Collier, Trisha L. Coady, Kevin P. O'Hara, and Scott A. Roberts) with aggregate grant date fair values ranging from $360,000 to $450,000 per executive. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure, and would materially affect investor assessment of executive compensation and retention incentives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
The disclosure centers on the Board's election of Mark C. Krebs as a director (Class I) of both the Company and the Bank on September 21, 2026, and his appointment to three Board committees. Although Krebs previously served as Treasurer and CFO until his retirement on June 30, 2025, and then as an advisor, the principal action disclosed here is his appointment to the Board—a governance role change material to investors assessing leadership composition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-23
Item 1.01
This disclosure reports an amendment to a merger agreement between Independence Realty Trust, Inc. (IRT) and Centerspace (CSR), in which IRT has elected to implement an alternative merger structure. The filing explicitly describes the entry into an "Amendment to the Merger Agreement" on September 22, 2026, modifying the structure of the Company Merger so that CSR merges into IRT Merger Sub rather than vice versa. This is a material modification to a previously disclosed material acquisition transaction that would result in a change of control and is clearly within the scope of Item 1.01 (Entry into a Material Definitive Agreement) and constitutes ma_activity.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-23
Item 7.01
IDT Corp declared a quarterly cash dividend of $0.07 per share, payable on October 14, 2026 to shareholders of record as of October 5, 2026.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-09-23
EX-99.1
VEON announced a new share buyback program to repurchase 3.9% of outstanding shares (72.5 million shares or 2.9 million ADSs) for approximately USD 200 million, with cancellation of all acquired shares. This is a material capital return to shareholders through a share-repurchase program, which falls under dividend_distribution as a form of return of capital. The program represents 27.5% of trailing-twelve-month Equity Free Cash Flow and a 5.5% yield, demonstrating materiality to investors assessing capital allocation and shareholder value creation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
The filing discloses a strategic collaboration between SharonAI and VAST Data to integrate VAST DataEnclave into SharonAI's AI Factory platform. While the Item 4.01 header references "Changes in Registrant's Certifying Accountant," the actual substantive disclosure in the press release (Exhibit 99.1) concerns a material business partnership and product expansion—specifically the launch of a confidential AI capability for regulated customers across Australia and Asia-Pacific. This is a significant operational and strategic milestone for the company's platform, not an auditor change, making it an operational event that does not fit a more specific category.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-09-23
The filing discloses Beneficient's comprehensive strategy to eliminate fraudulent indebtedness asserted by HCLP Nominees (approximately $130 million in principal and accrued interest) and equity interests held by former CEO Brad Heppner following his May 2026 federal fraud conviction. The company is actively pursuing a consensual resolution before Heppner's October 2026 sentencing, or alternatively will pursue litigation against Heppner and related parties. This represents a material legal and financial matter arising from criminal fraud that directly impacts the company's balance sheet, capital structure, and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-23
The filing discloses entry into a material definitive agreement (Item 1.01) on September 18, 2026, whereby Greenpro Capital Corp. agreed to sell all issued and outstanding equity interests in six subsidiaries (the "F&A Entities") to Ms. Chen Yanhong for approximately US$446,486 in cash. This constitutes a material disposition of business assets. The transaction was approved by the audit committee and board of directors, and closing is expected before end of September 2026, subject to customary conditions.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-23
EX-99.1
Core AI received a Nasdaq notification on September 18, 2026, that it failed to maintain the minimum shareholders' equity of $2,500,000 required by Nasdaq Listing Rule 5550(b)(1), with shareholders' equity of only $2,429,389 as of June 30, 2026. The company has 45 days to submit a compliance plan and up to 180 days to regain compliance, or face delisting. This is a direct notice of non-compliance with continued listing standards and explicit delisting risk.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-23
EX-99.1
This announcement discloses a 1-for-6 share consolidation approved by the board and shareholders at an Extraordinary General Meeting on August 10, 2026, effective October 7, 2026. While the consolidation is a capital structure change, the disclosure focuses on the governance action (shareholder approval and board authorization) and its mechanics rather than a discrete financial event. The stated purpose is to increase per-share trading price and maintain NYSE American listing compliance, making it material to investors assessing the registrant's capital structure and exchange listing status.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-23
The filing discloses a strategic corporate update following the completion of a business combination on July 14, 2026, outlining the company's post-merger structure, clinical development priorities (LT-100 program), and expansion of the ai² platform. While the merger itself was a material M&A event, this 8-K Item 7.01 disclosure focuses on operational strategy and clinical development priorities rather than the M&A transaction itself. The update describes organizational restructuring (Glucotrack Technologies as subsidiary, Lōkahi Therapeutics as parent focus), clinical protocol submission for LT-100, and platform expansion initiatives—all operational and strategic in nature.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-23
Item 3.03
Brightline Interactive received a Nasdaq Staff Determination to delist on September 11, 2026, for failing to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has appealed the determination and implemented a 1-for-8 reverse stock split to regain compliance with the listing standard.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-09-23
The filing discloses two interim services agreements effective September 22, 2026: (1) an Interim Vice President, Finance & Administration Services Agreement with 2752128 Ontario Ltd. (Kelly White's entity) for US$2,500/month through December 31, 2026, and (2) an Interim Strategic Management Services Agreement with Miranda Water Technologies for US$1,500/month through December 31, 2026, with services provided by directors Michael A. Skinner, Ryan D. Moore, and Catia Skinner. These are compensatory arrangements for officers and directors, disclosed under Item 5.02(e), replacing prior interim agreements. While Item 1.01 frames these as "material definitive agreements," the substance is compensatory arrangements for named executives and directors, making exec_compensation the most precise classification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-23
Item 1.01
The company amended its existing Credit Agreement to extend the maturity date from September 30, 2026 to December 31, 2026, preserving and extending a material direct financial obligation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-09-23
The 8-K discloses preliminary unaudited financial results for fiscal year ended June 30, 2026 via a press release (Exhibit 99.1) filed under Item 2.02. The filing reports significant metrics including 85% revenue growth to $20.1 million, second consecutive year of positive net income (~$2.0 million), cash more than doubling to $15.4 million, and stockholders' equity of $21.1 million (versus prior-year deficit). These preliminary results are material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 1.01
Evofem entered into a Manufacturing Agreement with Zhaoke to become a second manufacturer and supplier of PHEXX®. This is a material operational and strategic event—adding manufacturing capacity, improving supply chain flexibility, and reducing unit costs by 40% or more—but it does not constitute a merger, acquisition, disposition, or change of control (ma_activity). The agreement is a material supply/manufacturing contract that supports the company's growth strategy and is best classified as an operational event rather than a financial or governance matter.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Eva Live Inc. entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC granting the investor the right to purchase up to $10,000,000 of common stock at $2.00 per share, plus issued a warrant to purchase 275,000 shares at $0.01 per share. The warrant and shares were offered in a private placement exempt from registration under Section 4(a)(2) and Rule 506(b). This is a classic dilutive equity issuance to raise capital, with the warrant exercise price of $0.01 being substantially below market, creating significant dilution to existing shareholders.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-23
The 6-K discloses completion of an acquisition on September 22, 2026, whereby Xiamen Chunshang (a wholly-owned subsidiary of Meiwu Technology) acquired 100% equity interests of Xiamen Hemeitong for RMB 235.2 million (~$35 million) in cash. This is a material M&A transaction involving a direct financial commitment and change in corporate structure, fitting the ma_activity classification for completion of a material acquisition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-23
Item 5.07 discloses the results of a stockholder vote on an amendment to increase authorized common shares from 400 million to 1.6 billion shares. The proposal was approved with 166,151,087 shares (50.44% of outstanding) voting in favor. This is a material governance event affecting the company's capital structure and future dilution potential.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
The filing discloses the appointment of Sheng-Yih Chang as Chief Executive Officer and Chairman of the Board effective September 21, 2026, following the resignation of Kewei Huang. While both a departure and appointment occur, the principal disclosed action centers on the appointment of Chang to the top leadership roles. Chang's prior service as CEO (April 2024–September 2026) and CFO (June 2018–April 2024) establishes his continuity and qualifications. This is material to investors as it affects the registrant's leadership structure and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-09-23
The filing's primary disclosure is the results of an extraordinary general meeting held on September 23, 2026, where shareholders voted on three proposals: the Extension Proposal (to extend the business combination deadline by up to 12 months), the Trust Amendment Proposal, and the Adjournment Proposal. The Extension Proposal and Trust Amendment Proposal were both approved with 2,858,762 votes in favor and 1,357,803 against, with 4,216,565 ordinary shares represented at the meeting. This is a material shareholder vote result under Item 5.07, though the filing also includes a CEO loan (Item 2.03) and bylaw amendments (Item 5.03).
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-23
EX-99.1
This announcement discloses a 1-for-9 share consolidation and reduction of par value from US$0.8064 to US$0.000001 per share, effective September 28, 2026. While the board approved this action under BVI law without shareholder vote, the consolidation materially alters the capital structure and share count (reducing Class A shares from 6.77M to 752K), affecting all shareholders' holdings and the company's authorized share capacity. This is a governance-driven capital structure modification that would affect a reasonable investor's assessment of share ownership and dilution risk.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-23
The filing discloses entry into a Fourth Amendment to a Member Interest and Asset Exchange Agreement dated September 22, 2026, under Item 1.01. The transaction involves a reverse triangular merger of TLSS's subsidiary with Patriot Glass Solutions (PGS), whereby TLSS will acquire an 80% membership interest in PGS and four nanotechnology patents in exchange for $4.75 million in Series J Senior Convertible Preferred Stock. This is a material acquisition activity with a defined purchase price and expected closing by October 1, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-23
The filing discloses the closing of a business combination between Hennessy Capital Investment Corp. VII (a SPAC) and ONE Nuclear Energy LLC, effective September 23, 2026. The combined entity was renamed "ONE Nuclear Energy Inc." and its common stock commenced trading on Nasdaq under ticker "ONEN." This represents completion of a material acquisition/change of control transaction, with the SPAC domesticating as a Delaware corporation and ONE Nuclear becoming a wholly-owned subsidiary. The transaction is explicitly described as a "Business Combination" and is material to investors as it fundamentally transforms the registrant's business and capital structure.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-23
EX-99.1
Fast Track Group announced that Nasdaq will delist its Class A ordinary shares from The Nasdaq Capital Market effective ten days after filing Form 25-NSE with the SEC. The delisting results from the Company's failure to satisfy the US$1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This is a material event that directly affects the registrant's listing status and trading venue, though the Company will continue trading on OTC Markets and remain a reporting company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
First Breach announced the successful completion of its first untethered flight of a proprietary drone prototype, a significant operational and product development milestone. The filing discloses progress toward completing initial prototypes in Q4 2026 and scaling production in Q2 2027, supported by a strategic agreement with Hellbender for engineering and manufacturing. This represents a material operational achievement in the company's unmanned systems program, though it does not fit neatly into specific event categories like M&A, earnings, or executive changes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-23
The filing discloses results of OneMedNet's 2026 Annual Meeting of Stockholders held on September 18, 2026, with detailed voting tallies for four proposals: election of three Class III directors, ratification of auditor WithumSmith+Brown, approval of an amended 2022 Equity Incentive Plan increasing authorized shares by 1,000,000, and approval of a reverse stock split authorization (1-for-5 to 1-for-20 ratio). Item 5.07 explicitly addresses submission of matters to a vote of security holders, and the filing presents the vote counts and outcomes for each proposal, which is the core disclosure required for shareholder vote results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
The filing discloses exploration drilling results from the Selebi Main deposit in Botswana, including assay results from drill hole SMD-26-219 (7.55 metres grading 6.48% CuEq) and a visual intercept from SMD-26-217 that extends a high-grade trend and discovers a new mineralized zone. This is an operational/exploration milestone for a mineral exploration company, not a routine administrative disclosure. While the company is a mineral exploration entity and such results are part of its core business, the specific discovery of a new third mineralized zone and extension of the high-grade trend to 1.5 kilometres represents material progress toward resource expansion that would affect a reasonable investor's assessment of the company's exploration success and future resource potential.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-23
The filing discloses results of a Special Meeting of Stockholders held on September 23, 2026, where shareholders voted on three proposals: (1) increasing authorized common shares from 25 million to 150 million, (2) approving a discretionary reverse stock split at a 1-for-2 to 1-for-20 ratio, and (3) adjournment authority. All three proposals were approved with detailed vote tallies provided. This is a classic Item 5.07 shareholder vote results disclosure, material because the authorized share increase and reverse split authority materially affect the capital structure and shareholder interests.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-23
FG Nexus Inc. entered into a subscription agreement on September 17, 2026, to acquire 1,818,182 shares of common stock in FG Communities, Inc. for $10,000,001 ($5.50 per share), with closing on September 21, 2026. This constitutes a material acquisition of equity interests in a privately held real estate investment company with a portfolio of 96 manufactured housing communities. The transaction was disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and involved related-party considerations requiring Special Committee and independent financial advisor review, indicating materiality to investors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-23
Item 5.02
The Board granted 188,222 RSUs to four officers and directors on September 16, 2026, including CEO Deven Soni (81,118 RSUs, $383,689 target value), Chief Credit Officer Christopher Creatura (43,680 RSUs, $206,606), and board members David Hackett and Jaime Leverton (31,712 RSUs each, $150,000 each) under the 2024 Incentive Plan.
View raw filing on EDGAR →
6-K
Governance Other
confidence 65%
filed 2026-09-23
EX-99.1
VS Media Holdings Ltd is seeking shareholder approval at an extraordinary general meeting scheduled for October 9, 2026, for two material proposals: (1) a corporate restructuring involving the disposal of loss-making subsidiaries for US$1.00, and (2) adoption of amended articles including a company name change to 'Forcendra Holding Limited' and new share redemption rights and governance modifications.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-09-23
Item 8.01
MariMed announced the filing of a definitive proxy statement seeking stockholder approval of a proposed reverse stock split (1-for-50 to 1-for-100 ratio) at a special meeting scheduled for October 28, 2026. The reverse split is intended to position the company for potential listing on a U.S. national securities exchange. This is a governance event involving a shareholder vote on a capital structure amendment, distinct from the shareholder_vote_results category (which applies after voting occurs) and best classified as governance_other since it announces the proxy filing and solicitation rather than vote results.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-23
EX-99.1
Blue Moon Metals has signed a definitive agreement to acquire 100% of the Turner Copper-Gold VMS deposit from Gold Coast Mining Inc. for total consideration of approximately US$31.7 million in cash and equity (US$4.7M cash plus 4.78M shares worth ~US$27M plus contingent milestone payments). This is a material acquisition that expands the company's Western U.S. critical mineral hub-and-spoke model and is expected to close in November 2026, subject to TSX-V approval.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-23
Item 8.01
News Corporation disclosed daily buy-back notifications under its $1 billion repurchase program authorized July 15, 2025, with approximately $493.7 million deployed to date across Class A and Class B common stock. Share repurchase programs constitute a form of capital return to shareholders and are classified as dividend_distribution events under the taxonomy, as they represent a return of capital to security holders alongside or in lieu of cash dividends.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-23
Item 3.02
Decoy Therapeutics entered into a warrant inducement agreement with an institutional investor, issuing 2,368,868 unregistered new warrants (representing 200% of exercised existing warrants) in a private placement under Section 4(a)(2) of the Securities Act. The transaction generated $3.85 million in gross proceeds from the exercise of 1,184,434 Series B Milestone Warrants and included a reduction in exercise prices of existing warrants from $5.91 to $3.25 per share, resulting in substantial dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-23
Item 2.02
General Mills issued a press release on September 23, 2026, reporting financial results for its first quarter ended August 30, 2026, disclosing net sales of $4.4 billion (down 3%), operating profit of $634 million (down 63%), and diluted EPS of $0.74 (down 67%), along with reaffirmed full-year fiscal 2027 guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 5.02
LaTanya Langley is being appointed to a new executive role as Chief Administrative and Legal Officer and Corporate Secretary, effective October 1, 2026. Although she is departing her prior role as Chief People Officer, the principal disclosed action is the appointment to a more senior position overseeing legal and administrative functions. The appointment of a named executive to a C-suite role is material to investors assessing the company's leadership structure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-23
Item 2.02
Stitch Fix announced its financial results for the fourth quarter and full fiscal year 2026 ended August 1, 2026, including net revenue of $1,348.1 million (6.4% YoY growth), net loss of $12.6 million, and forward guidance for fiscal 2027 projecting revenue of $1.310–$1.360 billion. The press release is furnished as Exhibit 99.1 and includes consolidated financial statements, cash flow data, and management commentary from CEO Matt Baer. This is a standard quarterly/annual earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
Sabrina Farmer was appointed to Flywire's Board of Directors as a Class II director effective September 22, 2026, with her term expiring at the 2029 annual meeting. She was assigned to the Nominating and Corporate Governance Committee and will receive initial and annual RSU awards totaling $350,000 and $175,000 respectively.
View raw filing on EDGAR →